Cargando…

Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study

BACKGROUND: Achieving optimal symptom control with minimal side effects is a major goal in clinical practice. Dual-agent dopamine receptor agonist (DA) therapy in Parkinson’s disease (PD) may represent a promising approach to treatment, as the combination of different pharmacokinetic/pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jong-Min, Chung, Sun Ju, Kim, Jae Woo, Jeon, Beom Seok, Singh, Pritibha, Thierfelder, Stephan, Ikeda, Junji, Bauer, Lars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364324/ https://www.ncbi.nlm.nih.gov/pubmed/25879416 http://dx.doi.org/10.1186/s12883-015-0267-7

Ejemplares similares

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
por: Talty, Ronan, et al.
Publicado: (2022)

Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists
por: Ikeda, Ken, et al.
Publicado: (2016)

Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease
por: Kim, Han-Joon, et al.
Publicado: (2011)

Transdermal rotigotine for the perioperative management of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2010)

Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2016)

Behavioral and Neurophysiological Effects of Transdermal Rotigotine in Atypical Parkinsonism
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Transdermal rotigotine for the perioperative management of restless legs syndrome
por: Högl, Birgit, et al.
Publicado: (2012)

Dropped head sign induced by transdermal application of the dopamine agonist rotigotine in parkinsonian syndrome: a case report
por: Dohm, Christoph P, et al.
Publicado: (2013)

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects
por: Cawello, Willi, et al.
Publicado: (2013)

Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation
por: Ogawa, Takashi, et al.
Publicado: (2018)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
por: Gorgoraptis, Nikos, et al.
Publicado: (2012)

Rotigotine Transdermal Patch in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Zhou, Chang-Qing, et al.
Publicado: (2013)

Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)

A Study for Expanding Application Sites for Rotigotine Transdermal Patch
por: Kujirai, Hitoshi, et al.
Publicado: (2020)

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study
por: Pagonabarraga, Javier, et al.
Publicado: (2015)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations
por: Kesayan, Tigran, et al.
Publicado: (2015)

Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hoc analysis of the RECOVER study
por: Kassubek, Jan, et al.
Publicado: (2014)

Critical appraisal of rotigotine transdermal system in management of Parkinson’s disease and restless legs syndrome – patient considerations [Corrigendum]
Publicado: (2016)

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience
por: Raeder, Vanessa, et al.
Publicado: (2021)

Efficacy and Safety of Rotigotine Transdermal Patch on Neuropsychiatric Symptoms of Parkinson's Disease: An Updated Meta-Analysis and Systematic Review
por: Yan, Junqiang, et al.
Publicado: (2021)

Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson’s disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER
por: LeWitt, Peter A., et al.
Publicado: (2012)

Dopamine receptor agonist rotigotine-loaded microspheres ameliorates sexual function deteriorated by fluoxetine in depression rats
por: Wang, Wenqian, et al.
Publicado: (2021)

An Update on Pharmacological, Pharmacokinetic Properties and Drug–Drug Interactions of Rotigotine Transdermal System in Parkinson’s Disease and Restless Legs Syndrome
por: Elshoff, Jan-Peer, et al.
Publicado: (2015)

Rotigotine Objectively Improves Sleep in Parkinson's Disease: An Open-Label Pilot Study with Actigraphic Recording
por: Calandra-Buonaura, Giovanna, et al.
Publicado: (2016)

Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post Hoc Analysis
por: Giladi, Nir, et al.
Publicado: (2016)

Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson’s disease
por: Lau, Yue Hui, et al.
Publicado: (2022)

Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
por: Högl, Birgit, et al.
Publicado: (2010)

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey
por: Rizos, A., et al.
Publicado: (2020)

The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study
por: Suzuki, Keisuke, et al.
Publicado: (2022)

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis
por: LeWitt, Peter A., et al.
Publicado: (2016)

Effects of Night-Time Use of Rotigotine on Nocturnal Symptoms in Parkinson's Disease
por: Vallderiola, Francesc, et al.
Publicado: (2015)

A clinical improvement of a idiopathic cervical dystonia in a patient treated with transdermal Rotigotine: a case-report
por: Mangiardi, Marilena, et al.
Publicado: (2020)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson’s disease
por: Ouchi, Mifuka, et al.
Publicado: (2022)

A Systematic Review of the Usage of Rotigotine During Early and Advanced Stage Parkinson's
por: Rajendran, Avanthika, et al.
Publicado: (2023)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

Preventive effect of a heparinoid-containing product on the application site reaction of the rotigotine transdermal patch in Parkinson’s disease: A pilot randomized clinical trial (the SkinHeRo study)
por: Koh, Jinsoo, et al.
Publicado: (2021)

Efficacy of Rotigotine at Different Stages of Parkinson’s Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage
por: Giladi, Nir, et al.
Publicado: (2016)

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
por: Moretti, Davide Vito, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lfei5levpvsbbs2mk091p856g1